Abstract
Abstract
Emerging technology is present in every field of life as well as increasing convenience in medical area. One of the most important steps taken in the name of healthy, safeand comfortable life with diabetes is the provision of continue glucose monitoring systems,and insulin and glucagon bihormonal secretion. In this article we have reviewed the latest developments in the artificial pancreas, which are still in their study and are in theprocess of approval.
References
- Kaynaklar 1.Çetinkalp Ş. Endokrinoloji 2017; 513-25. 2.Russell SJ, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goer-gen LG, Balliro C, Hillard MA, Nathan DM, Damiano ER. Outpa-tient glycemic control with a bionic pancreas in type 1 diabetes. NEngl J Med. 2014 Jul 24;371(4):313-25. doi: 10.1056/NEJ-Moa1314474. Epub 2014 Jun 15. 3.Xia J, Xu J, Li B, Liu Z, Hao H, Yin C, Xu D. Association betweenglycemic variability and major adverse cardiovascular and cereb-rovascular events (MACCE) in patients with acute coronary syndro-me during 30-day follow-up. Clin Chim Acta. 2017 Mar;466:162-166. doi: 10.1016/j.cca.2017.01.022. 4.PráznýM, Škrha J, Šoupal J, Jr JŠ. [Short-term and long-term glyce-mic variability and its relationship to microvascular complicationsof diabetes]. Vnitr Lek. 2016 Fall;62(Suppl 4):85-93. Czech. 5.Ahmad Haidar, Laurent Legault,Virginie Messier,Tina MariaMitre,Catherine Leroux,Rémi Rabasa-Lhoret. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, andconventional insulin pump therapy for glycaemic control in patientswith type 1 diabetes: an open-label randomised controlled crosso-ver trial. The Lancet, Diabetes&endocrinology 2015; (3)1:17-26.
Abstract
Öz
Gelişen teknoloji hayatın her alanında olduğu gibi tıp alanında da her geçen gün artan kolaylıklar sunmaktadır. Diyabet ile sağlıklı, güvenli ve konforlu yaşam adına atılan en önemli adımlardan biri sürekli glukoz monitör sistemleri ile birlikte insülin ve glukagonun birarada -bihormonal- sekresyonun sağlanmasıdır. Bu yazımızda henüz çalışmaları devam edenve onay aşamasına gelen yapay pankreas ile ilgili son gelişmeleri derledik.
References
- Kaynaklar 1.Çetinkalp Ş. Endokrinoloji 2017; 513-25. 2.Russell SJ, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goer-gen LG, Balliro C, Hillard MA, Nathan DM, Damiano ER. Outpa-tient glycemic control with a bionic pancreas in type 1 diabetes. NEngl J Med. 2014 Jul 24;371(4):313-25. doi: 10.1056/NEJ-Moa1314474. Epub 2014 Jun 15. 3.Xia J, Xu J, Li B, Liu Z, Hao H, Yin C, Xu D. Association betweenglycemic variability and major adverse cardiovascular and cereb-rovascular events (MACCE) in patients with acute coronary syndro-me during 30-day follow-up. Clin Chim Acta. 2017 Mar;466:162-166. doi: 10.1016/j.cca.2017.01.022. 4.PráznýM, Škrha J, Šoupal J, Jr JŠ. [Short-term and long-term glyce-mic variability and its relationship to microvascular complicationsof diabetes]. Vnitr Lek. 2016 Fall;62(Suppl 4):85-93. Czech. 5.Ahmad Haidar, Laurent Legault,Virginie Messier,Tina MariaMitre,Catherine Leroux,Rémi Rabasa-Lhoret. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, andconventional insulin pump therapy for glycaemic control in patientswith type 1 diabetes: an open-label randomised controlled crosso-ver trial. The Lancet, Diabetes&endocrinology 2015; (3)1:17-26.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Makaleler 1 |
| Authors | |
| Publication Date | April 10, 2017 |
| Published in Issue | Year 2017 Volume: 5 Issue: 4 |
